Abeona Therapeutics Inc. $ABEO Shares Acquired by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its stake in Abeona Therapeutics by 74.1%, now owning 119,274 shares valued at approximately $568,000.
• Several institutional investors have recently made significant moves, with 80.56% of Abeona Therapeutics' stock now held by such investors.
• Abeona Therapeutics reported an earnings per share of $1.71 for the last quarter, significantly exceeding analysts' estimates of a loss of ($0.39).

Trexquant Investment LP boosted its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) by 74.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,274 shares of the biopharmaceutical company's stock after acquiring an additional 50,758 shares during the period. Trexquant Investment LP owned 0.24% of Abeona Therapeutics worth $568,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Twinbeech Capital LP bought a new stake in Abeona Therapeutics during the fourth quarter valued at $58,000. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $67,000. Cannon Global Investment Management LLC bought a new position in shares of Abeona Therapeutics during the 1st quarter valued at about $67,000. Balyasny Asset Management L.P. bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $190,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at about $341,000. Institutional investors own 80.56% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Oppenheimer upped their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Friday, August 15th. Wall Street Zen lowered shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Stifel Nicolaus dropped their price objective on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, August 18th. Finally, Alliance Global Partners reiterated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $19.50.

Insider Activity at Abeona Therapeutics

In other news, Director Christine Berni Silverstein sold 13,093 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total transaction of $76,724.98. Following the completion of the transaction, the director directly owned 120,479 shares in the company, valued at approximately $706,006.94. The trade was a 9.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark Alvino sold 13,093 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $76,724.98. Following the transaction, the director owned 77,252 shares of the company's stock, valued at $452,696.72. The trade was a 14.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 150,685 shares of company stock worth $884,186. 5.40% of the stock is owned by company insiders.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $6.70 on Tuesday. The stock has a market capitalization of $343.58 million, a price-to-earnings ratio of 9.57 and a beta of 1.67. Abeona Therapeutics Inc. has a 12-month low of $3.93 and a 12-month high of $7.54. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The stock has a 50-day simple moving average of $6.52 and a 200 day simple moving average of $5.87.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $21.71 million. On average, research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.